Invention Grant
US08945563B2 Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
有权
使用结合受体酪氨酸激酶ALK的细胞外结构域的抗体治疗胶质母细胞瘤的方法
- Patent Title: Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
- Patent Title (中): 使用结合受体酪氨酸激酶ALK的细胞外结构域的抗体治疗胶质母细胞瘤的方法
-
Application No.: US13017925Application Date: 2011-01-31
-
Publication No.: US08945563B2Publication Date: 2015-02-03
- Inventor: Adrian Auf Der Maur , Alcide Barberis , Peter Lichtlen
- Applicant: Adrian Auf Der Maur , Alcide Barberis , Peter Lichtlen
- Applicant Address: CH Schlieren
- Assignee: Delenex Therapeutics AG
- Current Assignee: Delenex Therapeutics AG
- Current Assignee Address: CH Schlieren
- Agency: Lathrop & Gage LLP
- Agent James H. Velema, Esq.; Andrew T. Wilkins, Esq.
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; C07K16/30 ; A61K39/00
Abstract:
The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
Public/Granted literature
- US20110159008A1 Antibodies Binding To The Extracellular Domain Of The Receptor Tyrosine Kinase ALK Public/Granted day:2011-06-30
Information query
